Loss of ARID1A expression is associated with poor prognosis in small intestinal carcinoma

Histopathology

Volumn 66, Issue 4, 2015, Pages 508-516

  Kim, Min Jong ^a   Gu, Mi Jin ^a   Chang, Hee Kyung ^b   Yu, Eunsil ^c  

^a Yeungnam University College of Medicine   (South Korea)

^b Kosin University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

ARID1A; Carcinoma; Immunohistochemistry; P53; Small intestinal

Indexed keywords

PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; SMALL INTESTINE CARCINOMA; TISSUE MICROARRAY; UNDIFFERENTIATED CARCINOMA; ADENOCARCINOMA; CANCER GRADING; COLLOID CARCINOMA; INTESTINE TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SMALL INTESTINE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SIGNET RING CELL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84922777629     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12566     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014; 64; 9-29.
2. Chang HK, Yu E, Kim J et al. Adenocarcinoma of the small intestinal: a multi-institutional study of 197 surgically resected cases. Hum. Pathol. 2010; 41; 1087-1096.
3. Cobrin GM, Pittman RH, Lewis BS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer 2006; 107; 22-27.
4. Arber N, Hibshoosh H, Yasui W et al. Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Cancer Epidemiol. Biomarkers Prev. 1999; 8; 1101-1105.
5. Blaker H, Helmchen B, Bonisch A et al. Mutational activation of the RAS-RAF-MAPK and the wnt pathway in small intestinal adenocarcinomas. Scand. J. Gastroenterol. 2004; 39; 748-753.
6. Sutter T, Arber N, Moss SF et al. Frequent K-ras mutations in small bowel adenocarcinomas. Dig. Dis. Sci. 1996; 41; 115-118.
7. Wheeler JM, Warren BF, Mortensen NJ et al. An insight into the genetic pathway of adenocarcinoma of the small intestinal. Gut 2002; 50; 218-223.
8. Gu MJ, Kim JY, Park JB. Fascin expression predicts lymph node metastasis and worse survival in small intestinal carcinoma. Pathology 2014; 46; 21-24.
9. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011; 11; 481-492.
10. Guan B, Wang TL, Shih I. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011; 71; 6718-6727.
11. Lowery WJ, Schildkraut JM, Akushevich L et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int. J. Gynecol. Cancer 2012; 22; 9-14.
12. Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT. Loss of ARID1A expression and its relationship with PI3K-akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod. Pathol. 2013; 27; 983-990.
13. Jones S, Li M, Parsons DW et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum. Mutat. 2012; 33; 100-103.
14. Agrawal N, Jiao Y, Bettegowda C et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012; 2; 899-905.
15. Wang DD, Chen YB, Pan K et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012; 7; e40364.
16. Fujimoto A, Totoki Y, Abe T et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 2012; 44; 760-764.
17. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 2011; 43; 875-878.
18. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosom. Cancer 2007; 46; 745-750.
19. Bosse T, ter Haar NT, Seeber LM et al. Loss of ARID1A expression and its relationship with PI3K-akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod. Pathol. 2013; 26; 1525-1535.
20. Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 2011; 224; 328-333.
21. Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 2011; 43; 1219-1223.
22. Maeda D, Mao TL, Fukayama M et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int. J. Mol. Sci. 2010; 11; 5120-5128.
23. Vousden KH, Lane DP. P53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007; 8; 275-283.
24. Fadare O, Renshaw IL, Liang SX. Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J. Cancer 2012; 3; 129-136.
25. Fadare O, Gwin K, Desouki MM et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod. Pathol. 2013; 26; 1101-1110.
26. Allo G, Bernardini MQ, Wu RC et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod. Pathol. 2014; 27; 255-261.
27. Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH. Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum. Pathol. 2013; 44; 1365-1374.
28. Zhang Y, Xu X, Zhang M et al. ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosis. Tumour Biol. 2014; 35; 5701-5707.
29. Wiegand KC, Sy K, Kalloger SE et al. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Hum. Pathol. 2014; 45; 1258-1268.
30. Chou A, Toon CW, Clarkson A et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum. Pathol. 2014; 45; 1697-1703.
31. Huang HN, Lin MC, Tseng LH et al. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression and ARID1A expression. Histopathology 2014. Doi: 10.1111/his.12543.
32. Gu MJ, Bae YK, Kim A et al. Expression of hMLH1, hMSH2 and hMSH6 in small intestinal carcinomas. Hepatogastroenterology 2012; 59; 2228-2232.
33. Nishiyama K, Yao T, Yonemasu H, Yamaguchi K, Tanaka M, Tsuneyoshi M. Overexpression of p53 protein and point mutation of K-ras genes in primary carcinoma of the small intestinal. Oncol. Rep. 2002; 9; 293-300.
34. Svrcek M, Jourdan F, Sebbagh N et al. Immunohistochemical analysis of adenocarcinoma of the small intestinal: a tissue microarray study. J. Clin. Pathol. 2003; 56; 898-903.
35. Brueckl WM, Heinze E, Milsmann C et al. Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestinal. Cancer Lett. 2004; 203; 181-190.
36. Mao TL, Shih IM. The roles of ARID1A in gynecologic cancer. J. Gynecol. Oncol. 2013; 24; 376-381.
37. Mao TL, Ardighieri L, Ayhan A et al. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am. J. Surg. Pathol. 2013; 37; 1342-1348.
38. Rahman M, Nakayama K, Rahman MT et al. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum. Pathol. 2013; 44; 103-109.